MYC amplification in breast cancer: a chromogenic in situ hybridisation study
- Socorro Maria Rodriguez-Pinilla (pimaso{at}yahoo.es)
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, United Kingdom
- Robin L Jones (robin.jones{at}icr.ac.uk)
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, United Kingdom
- Maryou BK Lambros (maryou.lambros{at}icr.ac.uk)
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, United Kingdom
- Edurne Arriola (edurne.arriola{at}icr.ac.uk)
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, United Kingdom
- Kay Savage (kay.savage{at}icr.ac.uk)
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, United Kingdom
- Michelle James (michelle.james{at}icr.ac.uk)
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, United Kingdom
- Sarah E Pinder (sep43{at}cam.ac.uk)
- Jorge Sergio Reis-Filho (jorgerf{at}icr.ac.uk)
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, United Kingdom
- Published Online First 8 December 2006
Abstract
Aims: To analyse the correlation between MYC amplification and various clinico-pathological features and outcome in a cohort of 245 patients with invasive breast carcinoma treated with surgery followed by anthracycline-based chemotherapy. Given the high prevalence of MYC amplification in tumours of BRCA1 mutation carriers and the similarities between these and sporadic "basal-like" carcinomas, we sought to define the prevalence of MYC amplification in "basal-like" breast carcinomas.
Methods: MYC gene copy number was assessed on tissue microarrays containing duplicate cores of 245 invasive breast carcinomas by means of chromogenic in situ hybridisation using SpotLight C-MYC amplification probe and Chromosome 8 Centromeric probe(CEP8). Signals were evaluated at 400x magnification; 30 morphologically unequivocal neoplastic cells in each core were counted for the presence of the gene and CEP8 probes.
Results: Amplification was defined as a MYC:CEP8 ratio >2. Signals for both MYC and CEP8 were assessable in 196/245(80%) tumours. MYC amplification was found in 19/196 cases(9.7%) and was not associated with tumour size, histological grade, positivity for oestrogen receptor, progesterone receptor, HER2, epidermal growth factor, cytokeratins 14, 5/6 and 17, MIB1 or p53. Only 4% of basal-like carcinomas showed MYC amplification, compared to 8.75% and 10.7% of luminal and HER2 tumours. On univariate analysis, MYC amplification displayed a significant association with shorter metastasis-free and overall survival and proved to be an independent prognostic factor on multivariate survival analysis.
Conclusion: MYC amplification is not associated with "basal-like" phenotype and proved to be an independent prognostic factor for breast cancer patients treated with anthracycline-based chemotherapy.
